41353-91-7

Usage

Uses

Used in Organic Synthesis:
Spiro[oxirane-2,3'-quinuclidine] is used as a key intermediate in organic synthesis for its ability to contribute specific steric and electronic properties to the molecules being synthesized, facilitating the creation of a diverse range of chemical compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Spiro[oxirane-2,3'-quinuclidine] is employed as a building block for the production of biologically active molecules, leveraging its unique structural features to enhance the pharmacological potential of the resulting compounds.
Used in Drug Discovery and Development:
Spiro[oxirane-2,3'-quinuclidine] is utilized in drug discovery and development processes due to its demonstrated potential pharmacological activities in various biological assays, making it a promising candidate for the creation of new therapeutic agents.
Used in Research and Development of Biologically Active Molecules:
Spiro[oxirane-2,3'-quinuclidine] is used as a research target for the development of biologically active molecules, given its intriguing properties and the possibility of its application in creating novel pharmaceuticals with improved efficacy and selectivity.

Upstream product

• 3731-38-2 3-Quinuclidinone 
• 1774-47-6 trimethylsulfoxonium iodide 
• 1193-65-3 3-quinuclidinone hydrochloride 

Downstream Products

• 61573-79-3 3-hydroxy-3-(hydroxymethyl)-1-azabicyclo<2.2.2>octane 
• 1067881-02-0 3-hydroxy-3-acetoxymercaptomethylquiniclidine thiolacetate 
• 107220-27-9 trans-cevimeline 
• 107220-27-9 cevimeline 
• 173553-37-2 Cevimeline hydrochloride 
• 153504-70-2 (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] monohydrochloride hemihydrate 
• 1467663-56-4 3-hydroxy-3-[(1-ethoxyethyl)mercaptomethyl]quinuclidine benzoic acid salt 
• 107220-27-9 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine 
• 107220-27-9 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine 
• 107220-26-8 3-hydroxy-3-(mercaptomethyl)quinuclidine 

Relevant academic research and scientific papers

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal dementia (FTD).

Synthesis of three alpha 7 agonists in labeled form

In support of a program to develop an alpha 7 agonist as a treatment for Alzheimer's disease, three drug candidates, 1, 2, and 3, were prepared in labeled forms. Compound 1 was prepared in C-14 labeled form by lithiation of [2,6-14C2]2-chloropyridine and subsequent coupling with spirooxirane-2,3'-quinuclidine. When this same coupling was attempted using [3,4,5,6-2H4]2-chloropyridine, alcohol [2H 6]-6 was the major product indicating that the primary isotope effect for the lithiation step was significant enough to shift the reaction pathway. Therefore, an alternate site of labeling was used to prepare [2H 4]-1. [13C5]-2 was prepared in five steps from [13C5]2-furoic acid, but the C-14 labeled compound used [14C2]-1 as the starting material instead. [ 14C2]-3 was prepared in two steps from [carbonyl- 14C]nicotinic acid. Copyright

1,3-OXATHIOLANE DERIVATIVES, PROCESS FOR THE PREPARATION OF 1,3-OXATHIOLANE DERIVATIVES AND INTERMEDIATES THEREOF

This invention relates to 1,3-oxathiolane derivatives (I), processes for the preparation of 1,3-oxathiolane derivatives and intermediate compounds thereof.

NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE

The invention relates to a 1-aza-bicyclo[2.2.2]oct-2-en-3-ylmethyl acetate of the formula (I), wherein said compound is useful as a synthesis intermediate for the production of mequitazine.

Process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3')quiniclidine

An industrially acceptable process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine. The cis-isomer of 2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine is known generally as Cevimeline.

ARYLKYLAMINE SPIROFUROPYRIDINES USEFUL IN THERAPY

A compound of formula I, wherein NRR1 is attached at the 5- or 6-position of the furopyridine ring; R is hydrogen, C1-C4 alkyl, or COR2; R1 is (CH2)nAr, CH2CH═CHAr, or

Spiroazabicyclic heterocyclic compounds

PCT No. PCT/SE98/01364 Sec. 371 Date Oct. 29, 1998 Sec. 102(e) Date Oct. 29, 1998 PCT Filed Jul. 10, 1998 PCT Pub. No. WO99/03859 PCT Pub. Date Jan. 28, 1999A compound of formula wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H2 or F2; A is N or C(R2); G is N or C(R3); D is N or C(R4); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R1 is hydrogen or C1 to C4 alkyl; R2, R3, and R4 are independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, -CN, -NO2, -NR5R6, -CF3, -OSO2CF3 or R2 and R3, or R3 and R4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, -CN, -NO2, -NR5R6, -CF3, -OSO2CF3; R5 and R6 are independently hydrogen, C1-C4 alkyl, C(O)R7, C(O)NHR8, C(O)OR9, SO2R10 or may together be (CH2)jQ(CH2)k where Q is O, S, NR11, or a bond; j is 2 to 7, k is 0 to 2; R7, R8, R9, R10, and R11 are independently C1-C4 alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

SPIRO-AZABICYCLIC COMPOUNDS USEFUL IN THERAPY

There are provided new compounds of formula I: wherein R represents hydrogen or methyl; and n represents 1 or 2; or a pharmaceutically acceptable acid addition salt thereof, together with processes for preparing them, compositions containing them and their use in therapy. Compounds of formula I are expected to be useful in the treatment of psychotic disorders, intellectual impairment disorders and anxiety